Recombinant tumor necrosis factor alpha inhibits growth of methylcholanthrene-induced sarcoma and enhances natural killer activity of tumor-infiltrating lymphocytes in aging rats

Clicks: 372
ID: 268564
1993
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The effect of recombinant human tumor necrosis factor alpha (rHuTNF-alpha) on the growth of immunogenic, methylcholanthrene-induced sarcoma (MC-Sa) and natural killer (NK) cell activity of tumor-infiltrating lymphocytes (TIL) in adult and aging rats was investigated. In both groups of animals the gr …
Reference Key
m1993archivumrecombinant Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ziółkowska M;Nowak JJ;Janiak M;Ryzewska A;;
Journal archivum immunologiae et therapiae experimentalis
Year 1993
DOI
DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/8010877
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE animals pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't male Comparative Study Rats wistar adjuvants cytotoxicity cell division / drug effects tumor necrosis factor-alpha / pharmacology* experimental / drug therapy* sarcoma experimental / chemically induced lymphocytes killer cells pmid:8010877 m ziółkowska j j nowak a ryzewska immunologic / pharmacology* aging / immunology* immunologic / drug effects natural / drug effects* tumor-infiltrating / drug effects* methylcholanthrene neoplasm transplantation experimental / immunology*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.